Xencor reported $116.52M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.4B 300M Sep/2026
Arrowhead Research USD 450.82M 375.59M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Biogen USD 2.8B 60M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Cytokinetics USD 47.6M 19M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Xencor USD 116.52M 65.3M Sep/2026